MedMira (TSXV:MIR) Debt-to-EBITDA : -3.26 (As of Jul. 2024)

View and export this data going back to 1999. Start your Free Trial

What is MedMira Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

MedMira's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2024 was C$6.41 Mil. MedMira's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2024 was C$3.15 Mil. MedMira's annualized EBITDA for the quarter that ended in Jul. 2024 was C$-2.93 Mil. MedMira's annualized Debt-to-EBITDA for the quarter that ended in Jul. 2024 was -3.26.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for MedMira's Debt-to-EBITDA or its related term are showing as below:

TSXV:MIR' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -10.57 Med: -4.41 Max: 62.35
Current: -4.48

During the past 13 years, the highest Debt-to-EBITDA Ratio of MedMira was 62.35. The lowest was -10.57. And the median was -4.41.

TSXV:MIR's Debt-to-EBITDA is ranked worse than
100% of 270 companies
in the Biotechnology industry
Industry Median: 1.41 vs TSXV:MIR: -4.48

MedMira Debt-to-EBITDA Historical Data

The historical data trend for MedMira's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Debt-to-EBITDA Chart

MedMira Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

Debt-to-EBITDA

Get a 7-Day Free Trial

-10.57

62.35

-7.78

-5.88

-4.48

MedMira Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Debt-to-EBITDA	Get a 7-Day Free Trial															-6.62	-4.27	-7.15	-4.04	-3.26

Competitive Comparison of MedMira's Debt-to-EBITDA

For the Biotechnology subindustry, MedMira's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MedMira's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MedMira's Debt-to-EBITDA falls into.

MedMira Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

MedMira's Debt-to-EBITDA for the fiscal year that ended in Jul. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(6.408	+	3.152)	/	-2.134
	=	-4.48

MedMira's annualized Debt-to-EBITDA for the quarter that ended in Jul. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(6.408	+	3.152)	/	-2.932
	=	-3.26

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jul. 2024) EBITDA data.

MedMira (TSXV:MIR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

MedMira Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of MedMira's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

MedMira Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (TSXV:MIR) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

MMIRF:USA 47M:Germany 47M:Germany

Address

155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3

Website

https://www.medmira.com

MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.